Should patients with combined hyperlipidemia receive statin–fibrate combination therapy?
Antonio M Gotto Jr
Correspondence Weill Medical College of Cornell University, New York, NY USA
Email amg_editorial@med.cornell.edu
This article has no abstract so we have provided the first paragraph of the full text.
The metabolic syndrome is a combination of coronary risk factors that greatly enhance the risk of heart disease, with insulin resistance as an underlying pathology. A recent conference of three US heart disease prevention groups recommended combination statin and fibrate therapy to treat atherogenic dyslipidemia—elevated LDL cholesterol and triglyceride levels with or without low HDL cholesterol levels—which frequently accompanies the metabolic syndrome.1 This recommendation warrants consideration, although lifestyle changes remain the first line of management of this syndrome.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
